Plasma concentrations of pancuronium were measured in nine patients undergoing surgery because of total biliary obstruction. When compared with the averaged model-independent pharmacokinetic parameters obtained for normal patients, the terminal half-life of 270 min was more than twice normal (132 min, P< 0.001); the plasma clearance of 59 ml min" 1 was less than half the normal rate for pancuronium (123 ml min~l, P< 0.003). These significant alterations to the pharmacokinetics of pancuronium were associated with prolongation of neuromuscular blockade. Following a bolus injection of pancuronium 6 mg, there was a mean time of 114 min (normals 70 min, P< 0.05) before the evoked twitch response had returned to 5% of the control value. The pattern of urinary excretion of the drug and its metabolites did not differ from that of normal patients. To avoid excessive dosage during prolonged surgery for total biliary obstruction, it is recommended that supramaximal nerve stimulation be used to indicate the need for the administration of further doses of pancuronium.
Apparent "resistance", to the action of non-depolarizing neuromuscular blocking agents, in patients with liver disease, has been observed for tubocurarine (Dundee and Gray, 1953; El-Hakim and Baraka, 1963) and pancuronium (Nana, Cardan and Leitersdorfer, 1972; Ward, Adu-Gyamfi and Strunin, 1975) . However, in Ward's report some difficulty in antagonizing the effects of pancuronium in two patients with severe obstructive jaundice was noted, even though "resistance" was observed in all patients.
The purpose of this study was to investigate the influence of biliary obstruction on the disposition and neuromuscular blocking action of pancuronium bromide in man, and to compare the results obtained with those of normal patients.
METHODS

Patients
Nine patients undergoing surgery for correction of total biliary obstruction were investigated during anaesthesia which lasted from 2 to 4£ h. The biliary obstruction (extra-hepatic) was a result of either carcinoma or stones in the common bile duct. Table I lists the disorders and the characteristics of the patients. The patients had markedly increased serum concentrations of bilirubin and alkaline phosphatase (table II) Correspondence to E. J. T. 89 based on clinical findings and laboratory data, and was confirmed at operation in all cases. All patients appeared to have normal renal function. These patients were compared with a group of normal patients undergoing routine general anaesthesia for elective surgery, described in a previous report (Somogyi, Shanks and Triggs, 1976) . The patients with biliary obstruction were premedicated with a combination of pethidine 50-100 mg and atropine 0.4-0.6 mg. Anaesthesia was induced with thiopentone 200-400 mg and maintained with a combination of nitrous oxide and oxygen. No additional narcotic analgesics were given but, for a few patients, supplementary halothane was added when the depth of anaesthesia was deemed inadequate. During the course of the operation, patients were given replacement volumes of normal saline and whole blood. Each patient received a 6-mg i.v. bolus injection of pancuronium bromide (Pavulon, Organon), not less than 30 min after induction of anaesthesia. In three patients additional maintenance doses of pancuronium were administered when the twitch response returned to 25% of its control value.
Biological fluid collection
In those patients (n = 6) who received a single dose of pancuronium, venous blood samples were obtained just before the dose was given (blank) then at 5, 10, 15, 20, 30, 60, 90, 120, 180, 240, 360 and, where possible, 480 min after the dose, and also at the time of recovery from neuromuscular blockade (as assessed by muscle twitch). For the three patients who required additional maintenance doses of the drug, identical blood sampling procedures were employed over the timeinterval for each dose of pancuronium given. The urine output of the patients was measured throughout the course of the surgical procedure and an aliquot was taken. Urine was collected when possible, up to 24 h after administration of pancuronium. Blood samples were centrifuged after collection, and the plasma and urine were frozen and stored before analysis.
Pancuronium assay
Plasma concentrations of pancuronium were analysed by the spectrofluorimetric technique of Kersten, Meijer and Agoston (1973) . Pancuronium, together with its three known metabolites, was analysed in urine by a modification of the method of the above authors. Following initial TLC separation, pancuronium and its metabolites were removed from the plate and the normal fluorescence assay was employed using a Perkin-Elmer model 204 fluorimeter. Standards were run on each plate and the method was reproducible with a minimum measurable concentration of 0.25 y.g ml" 1 of urine of each compound. There was incomplete separation of the two monoacetyl drug metabolites; this was the experience of Buzello (1974) and Tanaka, Hioki and Shindo (1974) . However, recently Kinget and Michoel (1976) were successful in separating the two monoacetyl metabolites, but their method in our hands proved unsuccessful.
Neuromuscular response
The evoked mechanical twitch response of the patients was measured at the ring finger, using a modification of the technique described by Katz (1965) . A supramaximal stimulus was delivered to the ulnar nerve in the forearm at 0.2 Hz, and the resulting contraction recorded continuously from a Devices linear force displacement transducer. Not less than 20 min after the commencement of stimulation, the stable control values for twitch were taken, and the pancuronium was administered.
Pharmacokinetic analysis
The selection of an appropriate pharmacokinetic model has been the subject of much recent discussion (Boxenbaum, Riegelman and ElashofF, 1974; Wagner, 1976a) . Wagner (1976b) has emphasized the importance of not forcing all sets of data to a particular exponential equation.
The disposition of pancuronium could be described mathematically for each patient by either a bi-or a tri-exponential equation. The four parameters of the bi-exponential equation and the six parameters of the tri-exponential equation were iterated using the computer program Nonlin (Metzler, 1969) , and a nonlinear least squares fit of each set of data was obtained. Statistical differences between the normal and liver disease patient groups were analysed by the twotailed non-parametric Mann-Whitney U-test (Goldstein, 1967) .
RESULTS
From the computer non-linear fits it was found that use of the tri-exponential equation did not significantly improve on the fit obtained by the bi-exponential equation except in one case (patient 6). shows the computer-predicted fit of the equations, and the measured plasma concentration for this particular patient. Model-independent pharmacokinetic parameters were calculated (Wagner, 1976b) . The terminal phase plasma half-life (T^), plasma clearance, volume of distribution at steady-state (Fdgg) and the apparent volume of distribution (Vdp) are shown in table III, with the values obtained from a group of normal subjects. There were no statistically significant differences found in the volumes of distribution terms Fd^ and Vdp between the two groups. The former term is the more important of the two as it is independent of elimination processes (Klotz, 1976 ). Significant differences were found between the two groups in the terminal halflife, T ifi (P< 0.001) and plasma clearance (P< 0.003). The relief of biliary obstruction did not appear to affect the plasma clearance of pancuronium.
The duration of action of pancuronium (t) was considered to be the time from the onset of paralysis to the time when the twitch height had returned to 5% of control-95% paralysis. Table IV lists this time (t) together with the plasma concentration, concurrently measured, in subjects of both groups. The pharmacological data revealed an increased duration of action for the patients with liver disease (P< 0.05); however, because of the small number of normal patients (n = 5), this prolongation of action is probably an underestimate. In the normal group only one patient exhibited a duration of action greater than the shortest duration in the patients with biliary obstruction. No significant differences between the two groups were found in the plasma concentration at 95% paralysis.
Patient no. 7 received an additional dose of pancuronium (1 mg) following recovery from the first dose. The effect of this supplementary dose lasted (95% paralysis) 90 min, with recovery occurring at a plasma concentration of 0.13 jxg ml" 1 . Patient no. 8 received an additional 2 mg which lasted for 47 min and recovery occurred at a plasma concentration of 0.33 y.g ml"
1 . Patient no. 9, who received four additional 1-mg doses, had a duration of action for the four doses of 13,7,8 and 7 min respectively. However, an accumulation of effect appeared to occur since, following the last dose, 90% paralysis lasted for 40 min. The concurrent plasma concentrations corresponding to each time of recovery were 0.56, 0.53, 0.48 and 0.51 y.% ml" 1 respectively.
The 24-h urinary excretion of pancuronium and its metabolites is shown in table V. Because inadequate separation of the two monoacetyl metabolites of the drug occurred, the results were combined and are referred to as the monoacetate. An average of 41% of the dose was recovered as unchanged drug and 11 % as metabolites in the 24 h following drug administration, the principal metabolite being the monoacetate (table V) .
DISCUSSION
When pancuronium is administered as an i.v. bolus injection, it is distributed rapidly into various body tissues (Waser, 1973) . In normal patients it is usually eliminated rapidly from the body, the terminal halflife for pancuronium being reported as approximately 2 h (McLeod, Watson and Rawlins, 1976; Somogyi, Shanks and Triggs, 1976) . In man, the drug is eliminated chiefly in the urine; 41% of the total dose is excreted via the kidneys, largely as unchanged pancuronium . These workers reported that 15% of the urinary total was the monoacetate metabolite. In bile 11% (mean; range 0.1-29%) of the total dose was recovered from bile, with 5% being excreted as the monoacetate metabolite . A major rinding of the present study was that the patients with total biliary obstruction had a significantly reduced plasma clearance of pancuronium, a clearance less than half that found for normal patients (table III) . This was not because of a change in the apparent volume of distribution. The terminal plasma half-life of pancuronium was prolonged significantly, being twice that for normal patients.
In considering the mechanism of these changes, it is possible that the patients might have been suffering from renal failure. However, none became anuric, and the urinary excretion of pancuronium and its metabolites was similar to that reported from normal patients . It is interesting to note that the mean plasma clearance rate was similar to that of 53 ml min-1 reported for patients undergoing renal transplantation (Somogyi, Shanks and Triggs, 1977) .
With the possible exception of patient no. 9, none of the patients in this study showed "resistance" to the effects of pancuronium, suggesting that this phenomenon should be evaluated only in patients with liver disease, those with total biliary obstruction being excluded. The study also offers an explanation for the difficulty encountered in antagonism of neuromuscular blockade, as observed by Ward, Adu-Gyamfi and Strunin (1976) in two patients with severe obstructive jaundice. It is likely that their patients had very high plasma concentrations of pancuronium at the end of surgery.
Our data suggest a relationship between a plasma concentration of pancuronium of 0.25 [zg ml" 1 and an evoked twitch response at 5% of the control value. This does not negate the observations of Feldman and Tyrrel (1970) , made when the plasma concentration of a myoneural blocking drug decreases rapidly, but, rather, it reflects the continuation of high plasma concentrations in patients with slow clearance rates. The extreme case would occur if the plasma concentrations were maintained at a constant level, as when pancuronium is infused continuously at the same rate as it is cleared. Other studies are to be reported which suggest a relationship between the steady state concentration of pancuronium and the intensity of paralysis.
The slow rate of clearance of pancuronium by patients with total biliary obstruction would enable overdosage to occur easily during prolonged surgery. It is recommended that a nerve stimulator be used to monitor individual requirements for the administration of further relaxant.
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SUMARIO
Se midieron las concentraciones de plasma de pancuronio en nueve pacientes sometidos a cirugia debido a una obstruction biliar total. Al compararse con el modelo promediado, parametros farmacocineticos obtenidos para pacientes normales, el semiperiodo terminal de 270 min resulto mas que doble de la normal (132 min, P< 0,001); el despeje de plasma de 59 ml/min resulto menos que la mitad de la cantidad normal de pancuronio (123 ml/min, P< 0,003). Estos cambios significativos a la farmacocinetica del pancuronio fueron asociados con la prolongation del bloqueo neuromuscular. Siguiendo una inyeccion de bola de pancuronio 6 mg, transcurrio un tiempo medio de 114 min antes que la evocada reaction de contracciones (normales 70 min, P<0,05) volviera al valor de control de 5%. El problema de la excresion urinaria de la droga y los metabolitos no resulto diferente al de los pacientes normales. Para evitar una dosis excesiva durante cirugia prolongada de obstruction biliar total, se recomienda emplear estimulo nervioso supramaximal para indicar la necesidad para la administration de mas dosis de pancuronio.
